Filed under: life sciences
2 storiesThe archive, indexed. Every story carries its tags at the foot of the page.
Startup news
Claret Capital closes fourth growth debt fund at €575m
The London manager beat its own €500m target. What founders can borrow, and at what stage, has not been disclosed.
№ 198 · 7 September 2026
Biotech funding
US voucher worth up to $200m pulls rare-disease money west
The FDA's Priority Review Voucher scheme was signed back into law in February. UK rare-disease founders have no equivalent, and one of them says investors notice.
№ 87 · 17 August 2026